DERMATA THERAPEUTICS, INC. Shares Authorized
DERMATA THERAPEUTICS, INC. (DRMA) had Shares Authorized of 250.00 million shares as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Common Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:CommonStockSharesAuthorized · last filed 2026-08-11
- 2026-06-30: Common Stock, Shares Authorized 250.00M shares.
- 2026-03-31: Common Stock, Shares Authorized 250.00M shares.
- 2025-12-31: Common Stock, Shares Authorized 250.00M shares.
- 2025-09-30: Common Stock, Shares Authorized 250.00M shares.
| Period end | Common Stock, Shares Authorized |
|---|---|
| 2026-06-30 | 250.00M shares 10-Q · filed 2026-08-11 |
| 2026-03-31 | 250.00M shares 10-Q · filed 2026-05-13 |
| 2025-12-31 | 250.00M shares 10-Q · filed 2026-08-11 |
| 2025-09-30 | 250.00M shares 10-Q · filed 2025-11-14 |
| 2025-06-30 | 250.00M shares 10-Q · filed 2025-08-13 |
| 2025-03-31 | 250.00M shares 10-Q · filed 2025-05-14 |
| 2024-12-31 | 250.00M shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 250.00M shares 10-Q · filed 2024-11-13 |
| 2024-06-30 | 250.00M shares 10-Q · filed 2024-08-07 |
| 2024-03-31 | 250.00M shares 10-Q · filed 2024-05-15 |
| 2023-12-31 | 250.00M shares 10-K · filed 2025-03-17 |
| 2023-09-30 | 250.00M shares 10-Q · filed 2023-11-09 |
| 2023-06-30 | 250.00M shares 10-Q · filed 2023-08-10 |
| 2023-03-31 | 250.00M shares 10-Q · filed 2023-05-11 |
| 2022-12-31 | 250.00M shares 10-K · filed 2024-03-21 |
| 2022-09-30 | 250.00M shares 10-Q · filed 2022-11-10 |
| 2022-07-11 | 90.00M shares 10-K · filed 2024-03-21 |
| 2022-06-30 | 90.00M shares 10-Q · filed 2022-08-15 |
| 2022-03-31 | 90.00M shares 10-Q · filed 2022-05-16 |
| 2021-12-31 | 90.00M shares 10-K · filed 2023-02-21 |
| 2021-09-30 | 90.00M shares 10-Q · filed 2021-11-15 |
| 2021-08-14 | 90.00M shares 10-Q · filed 2022-08-15 |
| 2021-06-30 | 4.39M shares 10-Q · filed 2021-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |